GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM

GSA Capital Partners LLP purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 9,419 shares of the company’s stock, valued at approximately $2,305,000.

Several other institutional investors and hedge funds have also made changes to their positions in AXSM. Handelsbanken Fonder AB increased its position in Axsome Therapeutics by 216.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 42,400 shares of the company’s stock worth $10,378,000 after purchasing an additional 29,000 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Axsome Therapeutics by 14.9% in the 2nd quarter. GAMMA Investing LLC now owns 347 shares of the company’s stock valued at $85,000 after purchasing an additional 45 shares in the last quarter. Harbor Investment Advisory LLC purchased a new position in Axsome Therapeutics in the 2nd quarter valued at about $105,000. Seven Fleet Capital Management LP boosted its stake in shares of Axsome Therapeutics by 8.5% during the 1st quarter. Seven Fleet Capital Management LP now owns 14,055 shares of the company’s stock worth $2,376,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in shares of Axsome Therapeutics by 0.7% during the 1st quarter. Perceptive Advisors LLC now owns 149,950 shares of the company’s stock worth $25,345,000 after purchasing an additional 1,050 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Axsome Therapeutics

In other news, Director Roger Jeffs sold 286 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the completion of the sale, the director owned 58,653 shares of the company’s stock, valued at $14,439,195.54. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nick Pizzie sold 33,000 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at approximately $10,291,938.03. This represents a 43.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 200,766 shares of company stock valued at $46,685,646 over the last quarter. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $213.67 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.32. Axsome Therapeutics, Inc. has a 1-year low of $108.04 and a 1-year high of $260.19. The firm has a market capitalization of $11.19 billion, a P/E ratio of -56.98 and a beta of 0.65. The business’s 50-day simple moving average is $235.53 and its 200-day simple moving average is $205.05.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The business had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Equities analysts predict that Axsome Therapeutics, Inc. will post -2.7 EPS for the current year.

Analyst Upgrades and Downgrades

AXSM has been the subject of a number of analyst reports. Mizuho boosted their price objective on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday. Oppenheimer set a $280.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $258.00 target price on shares of Axsome Therapeutics in a research note on Monday, May 4th. Royal Bank Of Canada cut their price target on Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, TD Cowen increased their price target on Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $267.60.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.